Odonate, Inc.
Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
Market Cap
$48.4M
Volume
147.00
Cash and Equivalents
$95.0M
EBITDA
-$80.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$49.9K
52 Week Low
$2.8K
Dividend
N/A
Price / Book Value
0.92
Price / Earnings
N/A
Price / Tangible Book Value
0.92
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$80.7M
Return on Equity
86.14%
Return on Assets
-33.09
Cash and Short Term Investments
$95.0M
Debt
$4.8M
Equity
$71.4M
Revenue
N/A
Unlevered FCF
-$44.0M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick PremiumCompany Stock Pitches
No stock pitches match your current filters.
Try adjusting your filters or clearing them and trying again.